ASCO 2017: BCMA-Specific CAR T-Cell Therapy Sends Relapsed

ASCO 2017: BCMA-Specific CAR T-Cell Therapy Sends Relapsed/Refractory Numerous Myeloma Into Lasting Remission in an Early Trial Posted: 6/Five/2017 11:33:55 AM Last Updated: 6/Five/2017 11:33:55 AM Tweet this page Key Points Overall, the objective response rate was 100%, and thirty three patients (94%) had an evident clinical remission of myeloma (accomplish response, very good partial […]